By using a combination of genetic and pharmacological approaches, we found that pSMAD activation is increased in BRAF-mutant thyroid cancers, and that this is due to promiscuous engagement of activin and TGFβ family ligands with their corresponding receptors. This evidence concerns the gene TGFB1 and thyroid gland carcinoma.